Prostate Artery Embolization vs. Rezum: How Do These BPH Treatments Compare?

Key Takeaways

• Rezum uses water vapor generated by radiofrequency energy and treats the prostate through the urethra.
• PAE reduces blood supply to selected prostate tissue through an arterial catheter.
• Rezum has a current U.S. indication for men aged 50 or older with prostates from 30 to 80 cc, including central-zone and median-lobe hyperplasia.
• PAE does not have the same device-based 30 to 80 cc indication and has been studied in men with larger prostates, but candidacy remains individualized.
• Temporary catheter use for several days is common after Rezum because urinary symptoms can continue or worsen during the early healing phase.
• PAE can also cause urinary irritation and acute urinary retention, so some patients may require temporary catheterization.
• Published studies show favorable sexual-function profiles for both procedures, but sexual side effects can occur and cannot be ruled out.
• Indirect comparisons suggest both procedures can improve BPH symptoms, but the certainty of comparative evidence is limited.
• Selecting a BPH treatment should begin with determining the cause of the urinary symptoms and evaluating prostate anatomy and bladder function. North Star combines urologic evaluation with PAE expertise to help patients understand which treatment pathways may be appropriate.

Prostate artery embolization (PAE) and Rezum water vapor therapy are minimally invasive procedures used for lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH). Both can reduce obstruction without surgically removing the prostate, but they treat prostate tissue in very different ways.

Rezum is performed through the urethra and delivers controlled water vapor into selected prostate tissue. PAE is performed through an artery and reduces blood flow to selected parts of the prostate. In both procedures, symptom improvement develops as the treated tissue changes over time rather than from immediate surgical removal of a large amount of tissue.

The question for patients is not simply whether PAE or Rezum is better. Treatment selection depends on confirming the cause of the urinary symptoms and considering prostate volume and anatomy, bladder function, urinary retention, medical history, previous treatment, and personal priorities. There is no direct randomized trial proving that PAE or Rezum is superior for every patient.

At North Star Prostate Center, patients can approach that decision through multidisciplinary prostate care rather than beginning with the assumption that a specific procedure is the answer. 

North Star provides urology care alongside its PAE program, helping patients understand their urinary symptoms and how PAE, urologic procedures such as Rezum, or other BPH management options may fit into their care.

PAE vs. Rezum

What Is Rezum & How Does It Work?

Rezum is a transurethral water vapor therapy. A urologist passes the treatment device through the urethra and delivers short, controlled injections of sterile water vapor into selected obstructing prostate tissue. The vapor releases thermal energy within the tissue. Over time, the body’s healing response absorbs the treated tissue, decreasing the amount of tissue pressing on the urethra.
Current U.S. Boston Scientific prescribing and safety information states that Rezum is intended for men aged 50 and older with prostate volume from 30 to 80 cubic centimeters. The indication includes hyperplasia of the central zone and/or a median lobe.

The procedure does not leave a permanent mechanical implant. It does create a controlled inflammatory and healing response, which is why urinary irritation and temporary catheter use can be part of the early recovery.

How Does PAE Work?

PAE is an image-guided endovascular procedure. An interventional radiologist advances a catheter through an artery and uses angiography to identify the vessels supplying the prostate. Embolic particles are then delivered into selected prostatic arteries to reduce blood flow. The treated tissue undergoes ischemic change and the prostate can decrease in volume over time.
Because the prostate has variable arterial connections with the bladder, rectum, penis, and other pelvic structures, careful vessel mapping is central to the procedure. Non-target embolization is an uncommon but important potential complication. The Society of Interventional Radiology issued updated PAE practice guidance in June 2026.

North Star describes its PAE program as outpatient care generally performed without general anesthesia. The exact treatment plan depends on the patient.

Is PAE More Effective Than Rezum?

There is not enough direct evidence to say that PAE is universally more effective than Rezum, or vice versa. No major randomized trial has directly assigned patients to PAE versus Rezum and followed them head-to-head.

A systematic review and network meta-analysis comparing several minimally invasive BPH treatments found no consistently significant differences in symptom-score outcomes among PAE, Rezum, and other minimally invasive therapies at the time points available. However, comparisons were indirect, follow-up differed by treatment, and the evidence base was limited. Review the Journal of Vascular and Interventional Radiology analysis on PubMed.

Another network meta-analysis concluded that PAE, prostatic urethral lift, and water vapor thermal therapy can provide favorable risk-benefit profiles, while emphasizing that longer-term randomized comparisons are still needed. See the European Urology Focus analysis on PubMed.

For clinical decision-making, the important question is which procedure best fits the individual patient’s anatomy, urinary function, recovery preferences, and tolerance for procedure-specific risks.

Which Treatment Works Faster?

Both procedures generally require time for tissue response, but the early recovery patterns differ.
After Rezum, temporary prostate swelling can cause ongoing or temporarily worse urinary symptoms. Boston Scientific patient information states that some patients notice symptom relief in as soon as two weeks and that maximum benefit may occur within approximately three months. Review Rezum recovery information.

After PAE, urinary symptoms usually improve gradually as the treated prostate responds to reduced blood flow and decreases in volume. Some men improve within the first several weeks, while additional change can occur over the following months. The timeline varies substantially, especially in men with severe obstruction, urinary retention, or impaired bladder contractility.
Neither procedure should be presented as a guaranteed source of immediate relief. A patient who cannot urinate or has high-risk retention may need catheter drainage or other management while the underlying BPH treatment takes effect.

Will I Need a Catheter After PAE or Rezum?

Catheter Use After Rezum

Temporary catheterization is common after Rezum. Current Boston Scientific patient guidance states that men in the clinical study typically needed a catheter for about three days. The reason is that treated tissue can swell during the early healing phase, which can temporarily worsen obstruction. Some patients need a catheter for a shorter or longer period depending on prostate anatomy, baseline retention, post-void residual, and clinical recovery.

Catheter Use After PAE

PAE does not require a catheter for every patient, but urinary retention is a recognized possible adverse event. A patient who already depends on a catheter before treatment may need continued drainage during the early post-procedure period.

In a 2025 observational cohort, 119 of 126 catheter-dependent patients, or 94%, were catheter-free at three months after PAE. This was a single-center retrospective study, so the result should be presented as study data rather than a guaranteed success rate for every catheter-dependent patient. Review the 1,075-patient PAE cohort.

How Does Recovery Compare?

Rezum Recovery

Current patient guidance from Boston Scientific describes return to regular activities within a few days for many patients, but individual restrictions vary. The early healing period can include:

• Painful or frequent urination.
• Urgency.Blood in the urine or semen.
• Pelvic or penile discomfort.
• Temporary urinary retention or incomplete emptying.
• Temporary catheter use.
• Urinary tract infection in some patients.

Less common risks listed in current safety information include changes in ejaculatory volume, inability to ejaculate, worsening erectile dysfunction, urethral stricture, bladder-neck narrowing, and severe infection.

PAE Recovery

PAE is commonly performed without an overnight hospital stay, but recovery is not symptom-free for everyone. Post-embolization symptoms can include urinary burning, pelvic or local pain, urinary frequency, fatigue, and other temporary inflammatory symptoms.

A systematic review of 32 studies involving 2,116 patients found post-embolization syndrome was commonly reported after PAE, although definitions varied considerably across studies. Dysuria or urethral burning and local pain were among the most frequently reported components. Review the systematic review on PubMed.

Other recognized PAE risks include urinary tract infection, acute urinary retention, hematuria, hematospermia, access-site complications, and rare non-target embolization.

How Do PAE and Rezum Affect Sexual Function?

Both procedures have published data suggesting relatively favorable sexual-function outcomes, but neither should be described as having zero sexual risk.

In the pivotal randomized Rezum study, five-year follow-up reported a 4.4% surgical retreatment rate and no procedure-related sexual dysfunction or sustained de novo erectile dysfunction in the treated study population. A separate five-year sexual-function analysis also found preservation of erectile and ejaculatory function among assessed participants. Read the five-year Rezum trial and sexual-function analysis.

Current Rezum safety information nevertheless lists possible decreases in ejaculatory volume, anejaculation, worsening erectile dysfunction, and discomfort with ejaculation among potential adverse events. That is why the most accurate message is that sexual function is often preserved, not that sexual side effects cannot happen.

For PAE, systematic-review evidence suggests erectile function is often similar to baseline or to TURP, and ejaculatory disorders may be less common than after TURP. The certainty of several sexual-function comparisons remains low. Review the Cochrane evidence on PAE.

Does Prostate Size Matter?

Yes. This is one of the clearest differences in how the two procedures are described for U.S. patient selection.

The current U.S. Rezum indication is for prostate volume from 30 to 80 cc in men age 50 or older. It also includes central-zone and median-lobe hyperplasia. Patients outside that volume range should not be described as fitting the labeled device indication, even though studies may explore broader real-world use. See current Rezum product information.

PAE has been studied in men with larger prostates and does not use a device indication limited to 30 to 80 cc. The 2025 PAE cohort of 1,075 patients had a median prostate volume of 107 g, demonstrating that PAE is used in populations with larger glands. That does not mean prostate size alone makes someone a good PAE candidate. Review the PAE cohort on PubMed.

For both procedures, prostate anatomy, degree of obstruction, bladder function, urinary retention, and the patient’s broader medical situation must be considered alongside volume.

How Durable Are PAE and Rezum?

Both treatments have evidence of multi-year symptom improvement, but the studies are different enough that their retreatment percentages should not be treated as a direct contest.

The randomized Rezum study followed treated patients for five years and reported sustained symptom and flow improvements, with a 4.4% surgical retreatment rate in that study population. See the five-year trial on PubMed.

The 2025 PAE cohort reported sustained symptom improvement among patients with long-term follow-up and found that 16% of reintervention-eligible patients had a second prostatic intervention by up to 60 months. Because it was a retrospective single-center cohort, its percentage is not directly comparable with the randomized Rezum trial. See the PAE cohort on PubMed.

Durability should be discussed together with baseline prostate size, severity of obstruction, age, bladder function, medication use, and the possibility that BPH can continue to progress over time.

Who May Be Considered for Rezum?

A urologist may discuss Rezum when a patient has bothersome LUTS attributed to BPH and meets the clinical and device-selection requirements. Factors that can support discussion include:

• Age 50 or older.
• Prostate volume within the current 30 to 80 cc U.S. indication.
• Lateral, central-zone, or median-lobe BPH that is appropriate for water vapor treatment.
• A preference for a minimally invasive transurethral treatment rather than tissue resection.
• A desire to avoid a permanent prostate implant.
• A strong interest in preserving sexual function.
• Acceptance of a healing period that commonly includes several days of catheter use and temporary urinary irritation.

Rezum is contraindicated in some circumstances, including active urinary tract infection and certain implanted urologic devices, so individual screening is required.

Who May Be Considered for PAE?

PAE may be discussed when a patient has urinary symptoms attributed to BPH and wants to consider a treatment delivered through the arterial system rather than through the urethra. Potential reasons for evaluation include:

• Persistent moderate to severe BPH symptoms.
• Insufficient relief from medication or medication side effects.
• A preference to avoid transurethral thermal treatment or surgical tissue removal.
• A prostate larger than the labeled Rezum range, when PAE and other options are being considered.
• A desire to avoid a permanent mechanical implant.
• Concern about sexual side effects from other BPH procedures.
• Urinary retention or other complex symptoms that warrant multidisciplinary evaluation.

PAE still requires careful screening. Severe atherosclerotic disease, unfavorable pelvic arterial anatomy, renal function and contrast considerations, active infection, bladder dysfunction, and concern for another cause of urinary symptoms may change the treatment plan.

What Testing Is Needed Before Choosing PAE or Rezum?

BPH is only one possible cause of male lower urinary tract symptoms. An evaluation should establish whether the prostate is the main source of obstruction and whether the bladder can empty effectively.

Depending on the clinical situation, evaluation may include:

• Urinary symptom history and International Prostate Symptom Score (IPSS).
• Medication and prior BPH treatment history.
• Urinalysis and infection assessment.
• PSA testing and prostate cancer evaluation when indicated.
• Prostate volume and anatomy assessment.
• Urinary flow testing.
• Post-void residual measurement.
• Bladder-function evaluation or urodynamics in selected patients.
• Imaging needed for PAE vascular planning or other procedural planning.

At North Star, the diagnostic evaluation helps guide the treatment discussion rather than simply determine eligibility for PAE. The center provides urology care for urinary flow and prostate concerns alongside its PAE program. Evaluating the cause of symptoms, prostate anatomy, urinary flow, bladder function, and previous treatment can help patients better understand whether PAE or another BPH treatment approach deserves consideration.

PAE for BPH in Golden Valley and Minneapolis, Minnesota

North Star Prostate Center is located at 8401 Golden Valley Road, Suite 340, Golden Valley, Minnesota, serving men from Minneapolis, St. Paul, and the surrounding Twin Cities area.
North Star Prostate Center is structured to help men understand their prostate condition and available treatment paths, not simply to determine whether they qualify for PAE. By combining urologic evaluation with PAE expertise, the center can help patients comparing PAE vs. Rezum review prostate size, anatomy, urinary symptoms, bladder function, medication history, previous treatment, recovery considerations, and personal priorities before determining the next step.
Learn more about BPH and enlarged prostate care, review North Star’s PAE treatment information, or contact the center to request an evaluation.

Medical disclaimer: This article is for general educational purposes and is not a substitute for individual medical advice. BPH treatment depends on the cause and severity of urinary symptoms, prostate size and anatomy, bladder function, medical history, medications, prior procedures, and personal goals. A qualified clinician should determine which options are appropriate for an individual patient.